Most Fa­vored Na­tions rule for drug pric­ing: Gone, but not for­got­ten

The Cen­ters for Medicare and Med­ic­aid Ser­vices late Fri­day pro­posed to re­scind an­oth­er Trump-era drug pric­ing rule, this time for a rule that sought to low­er pre­scrip­tion drug costs by pay­ing no more for high-cost Medicare Part B drugs than the low­est price in some sim­i­lar in­ter­na­tion­al mar­kets.

The so-called Most Fa­vored Na­tion Mod­el in­ter­im fi­nal rule, which drug­mak­ers de­cried as price con­trols and Trump’s HHS pledged would save $85 bil­lion over sev­en years, nev­er got off the ground. Three dif­fer­ent law­suits, in­clud­ing one from Re­gen­eron (Part B spends more on Re­gen­eron’s Eylea than any oth­er drug), were filed to stop the rule from tak­ing ef­fect. The suits re­sult­ed in such a halt, mean­ing the rule was nev­er im­ple­ment­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER